Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers

NCT02996890 is registered in ClinicalTrials.gov with Themis Bioscience GmbH as lead sponsor.

NCT NCT02996890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02996890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers
Lead sponsor
Themis Bioscience GmbH
Phase
Phase 1
Overall status
Completed
Start date
May 3, 2017
Completion date
April 17, 2018
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

zika virus